Fero Industries, Inc FROI

After much anticipation, our new pick is  finally here. FROI poses a unique opportunity for us to involve ourselves with a stock that is poised for rapid growth. FROI’s Sucanon nutraceutical is one of only three products in the world with approval under the category of ‘Insulin Sensitizer’, used to treat Type 2 Diabetes.

Sucanon® has been approved for prescription sale in China , Peru and Mexico (Where it is distributed over-the-counter there under an exclusive agreement with Merck S.A. de C.V.), and as of this morning’s PR, will now also be expanding its consumer base into the Middle East.

We are particularly excited about this play, not only because they have a niche in a multi-billion dollar market, but because of the ripening conditions on the chart as well.

CALGARY, Alberta , Dec. 22, 2011 /PRNewswire/ — Fero Industries, Inc. (OTCQB: FROI.PK – News), the exclusive owner, producer and distributor of the Type-II diabetes treatment Sucanon®, is pleased to announce that it has entered into a Distribution Agreement with Premium Pharma Co. for the marketing and distribution of Sucanon® in several countries in the region ( Egypt , Saudi Arabia , United Arab Emirates , Bahrain , Kuwait , Qatar , Oman , Jordan , Lebanon , Iraq , Sudan and Libya ).

 

The 5-year Distribution Agreement calls for a minimum purchase of $13 million USD and gives Premium Pharma the exclusive right to market and sell Sucanon® through its established distribution channels and will begin shortly the regulatory process with the Ministries of Health for the sale of Sucanon®. Fero is also taking the necessary steps to comply with the United States government for this Agreement, and the companies expect to complete the licencing process and commence shipping of Sucanon® within a year.
Also have a look at this FROI video chart, and take note of the fact that BARCHART is giving FROI a “Buy” Rating

More Info can be found at www.feroindustries.com